By Therapeutic Area

Metabolic & Endocrine Risk Market Analysis

Cross-industry research covering Metabolic & Endocrine Risk across 1 market reportspanning Pharmaceuticals & Life Sciences – Molecular Diagnostics / Consumer Genomics.

1 Reports

1 Industries

Reports Covering Metabolic & Endocrine Risk

Direct to Consumer Genetic Sequencing Market to Reach USD 4.7 Billion by 2033 at 7.2% CAGR

Pharmaceuticals & Life Sciences – Molecular Diagnostics / Consumer Genomics·Market: USD 2.7 Billion (2025)·CAGR: 7.2%

Polygenic risk scores for type 2 diabetes, obesity predisposition, and lipid disorders are gaining traction as GLP-1 RA prescribers seek pre-treatment genetic stratification tools. The intersection with pharmacogenomics is commercially valuable: a consumer who tests positive for high metabolic risk is a high-probability candidate for a clinical follow-up tied to a GLP-1 RA or statin prescription.

16%

Market Share

9.1%

Segment CAGR

Explore More Segments

Browse all market segments across our research coverage.

View all segments